720
Participants
Start Date
April 17, 2023
Primary Completion Date
July 31, 2030
Study Completion Date
July 31, 2030
STX-478
STX-478 is a mutant-selective PI3Kα inhibitor
Fulvestrant
Fulvestrant
Ribociclib
Ribociclib
Palbociclib
Palbociclib
Letrozole
Letrozole
Anastrozole
Anastrozole
Exemestane
Exemestane
RECRUITING
Fondazione Policlinico Universitario Agostino Gemelli, Roma
NOT_YET_RECRUITING
Institut Jules Bordet, Anderlecht
NOT_YET_RECRUITING
UZ Leuven, Leuven
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
RECRUITING
Istituto Europeo di Oncologia, Milan
RECRUITING
Fondazione IRCCS San Gerardo dei Tintori, Monza
RECRUITING
USO-Virginia Cancer Specialists, PC, Fairfax
NOT_YET_RECRUITING
Hospital San Pedro, Logroño
RECRUITING
Hospital Clinico San Carlos, Madrid
RECRUITING
Hospital Universitario Fundación Jiménez Díaz, Madrid
RECRUITING
Hospital Universitario HM Sanchinarro, Madrid
RECRUITING
Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcón
NOT_YET_RECRUITING
Winship Cancer Institute, Emory University, Atlanta
RECRUITING
Institut Claudius Regaud, Toulouse
RECRUITING
Florida Cancer Specialists ORLANDO/DDU, Lake Mary
RECRUITING
Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest, Bordeaux
RECRUITING
Moffitt Cancer Center, Tampa
RECRUITING
Sarah Cannon Research Institute, Nashville
RECRUITING
The West Clinic, PLLC dba West Cancer Center, Germantown
RECRUITING
Stefanie Spielman Comprehensive Breast Center, Columbus
RECRUITING
UH Cleveland Medical Center, Cleveland
RECRUITING
Barbara Ann Karmanos Cancer Institute, Detroit
RECRUITING
START Midwest, Grand Rapids
RECRUITING
University of Iowa, Iowa City
NOT_YET_RECRUITING
Washington University, St Louis
RECRUITING
Centre Leon Berard, Lyon
RECRUITING
Louisiana State University Health Sciences Center, New Orleans
RECRUITING
University of Oklahoma Health Sciences Center, Oklahoma City
COMPLETED
Mary Crowley Cancer Research Center, Dallas
NOT_YET_RECRUITING
University of Texas Southwestern, Dallas
RECRUITING
University of Texas MD Anderson Cancer Center, Houston
RECRUITING
START San Antonio, San Antonio
RECRUITING
University of Colorado Cancer Center, Aurora
RECRUITING
START Mountain Region, West Valley City
NOT_YET_RECRUITING
Universitätsklinikum Erlangen, Erlangen
RECRUITING
UCSF Medical Center at Mission Bay, San Francisco
RECRUITING
Gustave Roussy, Villejuif
RECRUITING
Providence Cancer Institute Franz Clinic, Portland
RECRUITING
The Angeles Clinic & Research Institute, Los Angeles
COMPLETED
Yale-New Haven Hospital, New Haven
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Dana-Farber Cancer Institute, Boston
RECRUITING
Saint Luke's Cancer Institute, Kansas City
RECRUITING
Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas
NOT_YET_RECRUITING
University of Vermont Medical Center, Burlington
RECRUITING
Mater Misericordiae Hospital, Dublin
NOT_YET_RECRUITING
National Hospital Organization Kyushu Cancer Center, Fukuoka
NOT_YET_RECRUITING
Kansai Medical University Hospital, Hirakata
NOT_YET_RECRUITING
The Cancer Institute Hospital of JFCR, Kōtō City
NOT_YET_RECRUITING
Kyoto University Hospital, Kyoto
RECRUITING
Netherlands Cancer Institute, Amsterdam
RECRUITING
Erasmus MC, Rotterdam
RECRUITING
South Texas Accelerated Research Therapeutics (START) Barcelona- HM Nou Delfos, Barcelona
RECRUITING
Hospital Universitari Vall d'Hebron, Barcelona
Eli Lilly and Company
INDUSTRY